Dr. Martens (LON:DOCS) Reaches New 52-Week High Following Analyst Upgrade

Dr. Martens plc (LON:DOCS) hit a new 52-week high during mid-day trading on Tuesday after Peel Hunt upgraded the stock to a buy rating. The stock traded as high as GBX 86 ($1.16) and last traded at GBX 85.54 ($1.15), with a volume of 1096627 shares changing hands. The stock had previously closed at GBX 81.05 ($1.09).

Several other analysts also recently issued reports on the company. Royal Bank Of Canada lowered their price target on Dr. Martens from GBX 7,000 to GBX 6,000 and set a “sector perform” rating for the company in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Dr. Martens in a research report on Friday, July 11th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of GBX 6,000.

Dr. Martens Stock Up 4.2%

The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The firm’s 50-day moving average price is GBX 77.55 and its 200 day moving average price is GBX 65.44. The firm has a market cap of £819.81 million, a P/E ratio of 11.97, a PEG ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Thursday, June 5th. The company reported GBX 2.40 EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities research analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.